Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Kim

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Pain Management|July 13, 2017
Global cancer pain management: a systematic review comparing trials in Africa, Europe and North AmericaCharles A Odonkor, Gabriel Kim, Michael Erdek
PM & R : the Journal of Injury, Function, and Rehabilitation|March 17, 2020
A Novel Suspension System for Individuals with Proximal Transfemoral Amputations or Hip DisarticulationsEdward Dolomisiewicz, Gabriel Kim, Michael Corcoran, et al.
Military Medicine|April 27, 2021
Sarcoidosis Presenting as Dorsal Wrist Mass: A Case ReportGabriel Kim, Willie Banks, Bahman Sadr, et al.
Lab on a Chip|June 10, 2010
Simple haptotactic gradient generation within a triangular microfluidic channelJungyul Park, Deok-Ho Kim, Gabriel Kim, et al.
Cardiovascular Diabetology|September 7, 2013
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic controlMartin Ridderstråle, Robbyna Svaerd, Cordula Zeller, et al.
The Lancet. Diabetes & Endocrinology|June 21, 2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trialMartin Ridderstråle, Knut Robert Andersen, Cordula Zeller, et al.
Diabetes Care|June 16, 2014
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetesJulio Rosenstock, Ante Jelaska, Guillaume Frappin, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trialMichael Roden, Jianping Weng, Jens Eilbracht, et al.
Clinical Therapeutics|April 18, 2016
Safety and Tolerability of Empagliflozin in Patients with Type 2 DiabetesSven Kohler, Afshin Salsali, Stefan Hantel, et al.
Pflugers Archiv : European Journal of Physiology|December 30, 2021
Clues and new evidences in arterial hypertension: unmasking the role of the chloride anionNicolás Martín Kouyoumdzian, Gabriel Kim, María Julieta Rudi, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Pain Management|July 13, 2017
Global cancer pain management: a systematic review comparing trials in Africa, Europe and North AmericaCharles A Odonkor, Gabriel Kim, Michael Erdek
PM & R : the Journal of Injury, Function, and Rehabilitation|March 17, 2020
A Novel Suspension System for Individuals with Proximal Transfemoral Amputations or Hip DisarticulationsEdward Dolomisiewicz, Gabriel Kim, Michael Corcoran, et al.
Military Medicine|April 27, 2021
Sarcoidosis Presenting as Dorsal Wrist Mass: A Case ReportGabriel Kim, Willie Banks, Bahman Sadr, et al.
Lab on a Chip|June 10, 2010
Simple haptotactic gradient generation within a triangular microfluidic channelJungyul Park, Deok-Ho Kim, Gabriel Kim, et al.
Cardiovascular Diabetology|September 7, 2013
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic controlMartin Ridderstråle, Robbyna Svaerd, Cordula Zeller, et al.
The Lancet. Diabetes & Endocrinology|June 21, 2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trialMartin Ridderstråle, Knut Robert Andersen, Cordula Zeller, et al.
Diabetes Care|June 16, 2014
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetesJulio Rosenstock, Ante Jelaska, Guillaume Frappin, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trialMichael Roden, Jianping Weng, Jens Eilbracht, et al.
Clinical Therapeutics|April 18, 2016
Safety and Tolerability of Empagliflozin in Patients with Type 2 DiabetesSven Kohler, Afshin Salsali, Stefan Hantel, et al.
Pflugers Archiv : European Journal of Physiology|December 30, 2021
Clues and new evidences in arterial hypertension: unmasking the role of the chloride anionNicolás Martín Kouyoumdzian, Gabriel Kim, María Julieta Rudi, et al.
Pageof 2